期刊文献+

乳腺癌患者血清Leptin和VEGF的表达 被引量:4

Determination of Serum Leptin and Vascular Endothelial Growth Factor(VEGF) Contents in Patients with Breast Cancer
下载PDF
导出
摘要 目的:研究瘦素(Leptin)、血管内皮生长因子(VEGF)在乳腺癌患者血清中的表达,探讨其在乳腺癌诊断中的意义。方法:选择乳腺癌患者36例,乳腺良性增生病变患者31例,另选56例健康女性作为对照。分别用放射免疫分析(R IA)和酶联免疫吸附试验(ELISA)测定这些患者术前血清Leptin、VEGF。结果:正常对照组与良性病变组、乳腺癌组Leptin存在明显差异,正常对照组与乳腺癌组,良性病变组与乳腺癌组VEGF存在明显差异。乳腺癌患者术前血清Leptin、VEGF含量与有无淋巴结转移具有相关性。结论:乳腺癌患者术前血清Leptin、VEGF可作为鉴别乳腺良恶性肿瘤有无转移的指标。 Objective To investigate the serum expression of leptin and vascular endothelial growth factor (VEGF) in patients with breast cancer and assess its diagnostic significance. Methods Thirty - six patients with breast cancer and thirty - one patients with benign breast disorders entered this study. Serum concentration of leptin ( with RIA) and VEGF ( with ELISA) were determined in these patients before operation as well as in 56 controls. All the tested subjects were post - menopausal women. Results The difference between the leptin levels in the controls and patients with benign breast disorders was significantly; 80 was the difference between the leptin levels in controls and patients with breast cancer. Significant difference also existed between the VEGF levels in controis and patients with cancer as well as between the levels in patietns with benign breast disease and patients with cancer. Also, the serum leptin and VEGF levels in the cancerous patients with axillary metastasis were significantly higher than those in patietns without metastasis. Conclusion Serum leptin and VEGF might be taken as diagnostic tumor markers for malignanay and metastasis in patients with breast cancer.
出处 《放射免疫学杂志》 CAS 2006年第4期267-269,共3页 Journal of Radioimmanology
关键词 瘦素 血管内皮生长因子 乳腺癌 leptin, vascular endothelial growth factor, breast cancer
  • 相关文献

参考文献11

二级参考文献92

  • 1段伦喜,钟德午,胡辅珍,赵华,易文君,华颂文.胃癌中VEGF,F1t1和P53的表达意义(英文)[J].中国现代医学杂志,2004,14(12):38-41. 被引量:7
  • 2张红,洪晓涛.肝素联合VEGF预处理对人工血管内皮细胞生长及贴附率的影响[J].中国现代医学杂志,2004,14(12):75-76. 被引量:8
  • 3汪毅,任国胜,石远,王小毅.透明质酸酶与血管内皮生长因子在人乳腺癌侵袭与转移中的作用[J].肿瘤研究与临床,2005,17(2):80-82. 被引量:1
  • 4[1]Folkman J. What is the evidence that tumors are angiogenesisdependent? J Natl Cancer Inst, 1990, 82: 4~ 7.
  • 5[2]Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothe lial growth factor is a secreted angiogenic mitogen. Science, 1989,246:1306~ 1309.
  • 6[3]Keck PJ, Hauser SD, Krivi G , et al. Vascular permeability fac tor, an endothelial cell mitogen related to PDGF. Science,1989,240: 1309~1312.
  • 7[4]De Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 1992, 255:989~993.
  • 8[5]Collins P. Characterization of the increase in vascular permea bility induced by vascular permeability factor in vivo. Br J Pharmacol, 1993, 109: 195~199.
  • 9[6]Nagy J. Pathogenesis of ascites tumor growth: vascular perme ability factor, vascular hyperpermeability, and ascites fluid ac cumulation. Cancer Res, 1995, 55: 360~368.
  • 10[7]Harold F. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. AmJ Pathol, 1995, 146:1029~ 1039.

共引文献14

同被引文献27

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部